Quantbot Technologies LP acquired a new position in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,636 shares of the medical instruments supplier's stock, valued at approximately $791,000.
Several other large investors have also bought and sold shares of WST. Principal Financial Group Inc. grew its position in West Pharmaceutical Services by 2.3% during the 3rd quarter. Principal Financial Group Inc. now owns 91,756 shares of the medical instruments supplier's stock valued at $27,541,000 after purchasing an additional 2,037 shares during the last quarter. Swedbank AB purchased a new position in shares of West Pharmaceutical Services in the first quarter worth approximately $1,937,000. Cetera Investment Advisers boosted its stake in shares of West Pharmaceutical Services by 525.1% during the 1st quarter. Cetera Investment Advisers now owns 18,990 shares of the medical instruments supplier's stock worth $7,515,000 after acquiring an additional 15,952 shares during the last quarter. Atria Investments Inc lifted its position in shares of West Pharmaceutical Services by 19.4% during the 3rd quarter. Atria Investments Inc now owns 9,074 shares of the medical instruments supplier's stock valued at $2,724,000 after buying an additional 1,475 shares in the last quarter. Finally, Natixis Advisors LLC lifted its stake in shares of West Pharmaceutical Services by 9.7% during the 3rd quarter. Natixis Advisors LLC now owns 53,747 shares of the medical instruments supplier's stock valued at $16,133,000 after buying an additional 4,740 shares in the last quarter. 93.90% of the stock is owned by institutional investors.
West Pharmaceutical Services Price Performance
NYSE WST traded down $3.03 during trading hours on Monday, reaching $322.65. The company's stock had a trading volume of 399,952 shares, compared to its average volume of 570,663. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. The firm's 50-day moving average price is $308.81 and its 200-day moving average price is $312.62. West Pharmaceutical Services, Inc. has a 1 year low of $265.00 and a 1 year high of $413.70. The company has a market capitalization of $23.37 billion, a price-to-earnings ratio of 48.38, a PEG ratio of 24.71 and a beta of 1.01.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its earnings results on Thursday, October 24th. The medical instruments supplier reported $1.85 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.35. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. The company had revenue of $746.90 million for the quarter, compared to the consensus estimate of $709.62 million. During the same period in the previous year, the business earned $2.16 earnings per share. The firm's revenue for the quarter was down .1% on a year-over-year basis. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.64 EPS for the current fiscal year.
West Pharmaceutical Services Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 20th. Shareholders of record on Wednesday, November 13th were paid a $0.21 dividend. This is a boost from West Pharmaceutical Services's previous quarterly dividend of $0.20. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend was Wednesday, November 13th. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 12.46%.
Insider Transactions at West Pharmaceutical Services
In other news, VP Charles Witherspoon sold 703 shares of the firm's stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $310.40, for a total value of $218,211.20. Following the completion of the sale, the vice president now owns 1,253 shares in the company, valued at approximately $388,931.20. This trade represents a 35.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.53% of the company's stock.
West Pharmaceutical Services Company Profile
(
Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Read More
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
